FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates

FibroGen (FGEN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of$ 0.26. This compares to loss of $0.65 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 38.46%. A quarter ago, it was expected that this biotech drug developer would post a loss of$ 0.31 per share when it actually produced a loss of $0.33, delivering a surprise of -6.45%. Over the last four quarters, the company ha ...